SMG1 pseudogene 6 (SMG1P6)

SMG1 pseudogene 6 (SMG1P6) is a human pseudogene located downstream of the BOLA2 gene, sometimes observed as part of a readthrough transcript (BOLA2-SMG1P6)[1][7]. As a pseudogene, SMG1P6 does *not* encode functional protein product and is not itself an enzyme, receptor, or classical therapeutic target. Instead, its transcript has been proposed to function as a long non-coding RNA (lncRNA) or competing endogenous RNA (ceRNA), potentially modulating gene expression, for example in the neurovascular unit, by acting as a molecular 'sponge' for other RNA molecules[9]. There are no known small molecule drugs or inhibitors that directly target SMG1P6, and it is not classified as a therapeutic target. Its parent gene, SMG1, encodes a PI3K-related kinase central to the nonsense-mediated mRNA decay (NMD) pathway, but SMG1P6 itself does not share these enzymatic or cellular functions[1][3][9]. **Additional context:** While SMG1 (the protein-coding gene) is intensively studied for its kinase activity and importance in NMD and cell surveillance[4][6][8][10], SMG1P6 lacks any known protein product and is generally not addressed in the context of drug discovery or targeted pharmacology. SMG1P6's biological significance, if any, likely relates to its RNA-level effects rather than coded protein activity[9]. There is no clinical or biomarker role currently established for SMG1P6.

Other names

SMG1P6, nonsense mediated mRNA decay associated PI3K related kinase pseudogene 6smg-1 homolog, phosphatidylinositol 3-kinase-related kinase pseudogene